From our analysis, we observed that the pooled RR value for mortality in breast cancer patients was 1.64 (95% CI, 1.14–2.34), which suggests that patients with positive/higher PD-L1 expression have significantly poorer outcomes, as compared to patients with negative/lower PD-L1 expression. This evidence concerns the gene CD274 and breast carcinoma.